JP2009506301A5 - - Google Patents

Download PDF

Info

Publication number
JP2009506301A5
JP2009506301A5 JP2008524596A JP2008524596A JP2009506301A5 JP 2009506301 A5 JP2009506301 A5 JP 2009506301A5 JP 2008524596 A JP2008524596 A JP 2008524596A JP 2008524596 A JP2008524596 A JP 2008524596A JP 2009506301 A5 JP2009506301 A5 JP 2009506301A5
Authority
JP
Japan
Prior art keywords
pif
affinity reagent
abundance
protein isoform
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008524596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009506301A (ja
Filing date
Publication date
Priority claimed from GBGB0516058.5A external-priority patent/GB0516058D0/en
Application filed filed Critical
Publication of JP2009506301A publication Critical patent/JP2009506301A/ja
Publication of JP2009506301A5 publication Critical patent/JP2009506301A5/ja
Pending legal-status Critical Current

Links

JP2008524596A 2005-08-04 2006-08-04 Pifファミリーの新たなタンパク質アイソフォーム及びその使用 Pending JP2009506301A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0516058.5A GB0516058D0 (en) 2005-08-04 2005-08-04 New protein isoforms and uses thereof
US72208705P 2005-09-30 2005-09-30
PCT/GB2006/050232 WO2007015113A2 (en) 2005-08-04 2006-08-04 New protein isoforms of the pif-family and uses thereof

Publications (2)

Publication Number Publication Date
JP2009506301A JP2009506301A (ja) 2009-02-12
JP2009506301A5 true JP2009506301A5 (OSRAM) 2009-09-17

Family

ID=34984093

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008524596A Pending JP2009506301A (ja) 2005-08-04 2006-08-04 Pifファミリーの新たなタンパク質アイソフォーム及びその使用

Country Status (5)

Country Link
US (1) US20100223678A1 (OSRAM)
EP (1) EP1987356A2 (OSRAM)
JP (1) JP2009506301A (OSRAM)
GB (1) GB0516058D0 (OSRAM)
WO (1) WO2007015113A2 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5564249B2 (ja) 2006-06-23 2014-07-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌に関与するポリヌクレオチド配列およびポリペプチド配列
AU2009321508B2 (en) 2008-11-03 2015-03-12 Adc Therapeutics Sa Antibodies that specifically block the biological activity of a tumor antigen
US9958442B2 (en) 2009-02-11 2018-05-01 Duke University Sensors incorporating antibodies and methods of making and using the same
JP5433341B2 (ja) * 2009-08-04 2014-03-05 ホーユー株式会社 等電点電気泳動方法及び粗雑物除去の判定方法
JP5190423B2 (ja) * 2009-08-04 2013-04-24 ホーユー株式会社 2次元電気泳動方法
CN106146664B (zh) 2011-03-31 2021-09-07 Adc治疗股份有限公司 针对肾相关抗原1的抗体及其抗原结合片段
WO2013030032A1 (en) * 2011-08-26 2013-03-07 F. Hoffmann-La Roche Ag A method for predicting clinical benefit in the treatment of neurodevelopmental, neurological or neuropsychiatric disorders
CA3115623A1 (en) 2012-01-09 2013-07-18 Adc Therapeutics Sa Method for treating breast cancer
US9244946B2 (en) 2012-11-26 2016-01-26 International Business Machines Corporation Data mining shape based data
WO2015187227A2 (en) 2014-03-13 2015-12-10 Duke University Electronic platform for sensing and control of electrochemical reactions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319687B1 (en) * 1992-09-24 2001-11-20 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
US6613740B1 (en) * 1997-02-07 2003-09-02 Ramot University Authority For Applied Research And Industrial Development Ltd. Activity dependent neurotrophic factor III (ADNF III)
US20040038877A1 (en) * 2001-10-02 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003028543A2 (en) * 2001-10-03 2003-04-10 Pfizer Products Inc. Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO2003058021A2 (de) * 2002-01-11 2003-07-17 Xantos Biomedicine Ag Neue apoptose-induzierende dna-sequenzen
US20090162363A1 (en) * 2003-08-07 2009-06-25 Sofia Patricia Becerra Pedf-r receptor and uses
JP2005132738A (ja) * 2003-10-28 2005-05-26 Protein Express:Kk アルツハイマー病のタンパク質分子レベルにおける検出方法

Similar Documents

Publication Publication Date Title
Laroche et al. Diagnostic value of histamine and tryptase concentrations in severe anaphylaxis with shock or cardiac arrest during anesthesia
Ohtsuka et al. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging
US20140303041A1 (en) In vitro diagnostic devices for nervous system injury and other neural disorders
Bowser et al. Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations
EP3115785A2 (en) Process to diagnose or treat brain injury
CN107533048A (zh) 用于诊断脑损伤或神经退行性变的方法和组合物
US20220057409A1 (en) Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair
Castaneyra-Ruiz et al. Cerebrospinal fluid levels of tumor necrosis factor alpha and aquaporin 1 in patients with mild cognitive impairment and idiopathic normal pressure hydrocephalus
Nigro et al. Magnetic Resonance Parkinsonism Index and midbrain to pons ratio: Which index better distinguishes Progressive Supranuclear Palsy patients with a low degree of diagnostic certainty from patients with Parkinson Disease?
KR20230010687A (ko) 알츠하이머 병 평가용 단백질 마커
KR20170062478A (ko) 우울증 치료약의 선택지를 예측하는 방법
JP2018132526A (ja) 大うつ病性障害及び双極性障害のマーカー、検査方法、検査キット、及び治療薬のスクリーニング方法。
González-Quevedo et al. Increased serum S-100B and neuron specific enolase—Potential markers of early nervous system involvement in essential hypertension
Blandford et al. Interleukin-1 receptor antagonist: an exploratory plasma biomarker that correlates with disability and provides pathophysiological insights in relapsing-remitting multiple sclerosis
JP2009515183A5 (OSRAM)
JP5267452B2 (ja) 精神障害および/または腸のディスバイオシスのインビトロまたはエクスビボ診断方法
JP5295101B2 (ja) 神経変性疾患の経過及び予後の評価指標を提供するinvitro方法
US7709215B2 (en) Method for diagnosing and treating acute joint injury
JP7808340B2 (ja) 軽度認知障害検査
Li et al. Increased level of procalcitonin is associated with total MRI burden of cerebral small vessel disease in patients with ischemic stroke
US20060205024A1 (en) Method to diagnose and evaluate progression of Alzheimer's disease
Khodjieva et al. Correlation between neuroimaging, neurological deficits, and neurotrophic proteins in predicting rehabilitation potential in ischemic stroke patients
EP2802879B1 (en) Use of ccl23 as brain damage marker
CN103210312A (zh) 通过软骨酸性蛋白1 检测脑梗塞的方法
RU2694541C1 (ru) Способ прогнозирования функционального восстановления пациентов с ишемическим инсультом